Welcome back to the PharmTech Weekly Roundup! I’m Susan Haigney, lead editor of PharmTech. This week, the industry experienced accelerated digital transformation, regulatory evolution, and a strategic ...
Forecasts project rare disease drugs will exceed $400B in 2032 revenues (~21% of prescriptions), reinforcing their role as a core growth engine despite policy and competitive volatility. IRA revisions ...
For INTERPHEX NYC, taking place April 21-23, groninger will debut a formalized service structure and put a high-throughput ready-to-use processing platform in front of industry decision-makers.¹ Its ...
FDA replaces seven fragmented adverse event databases with AEMS, enabling real-time safety signal access for pharmaceutical manufacturers and researchers. On March 11, the FDA launched a unified ...
Vinay Prasad will leave FDA CBER by end of April, returning to UCSF after a one-year sabbatical, following a prior departure ...
AI accelerates biopharma from discovery to production, cutting cycle times by up to 40%.
Japan's largest pharma event returns May 2026 with 320 sessions spanning manufacturing, quality, CMC, and digital transformation.
A licensing structure assigns SteinCares end-to-end Latin America market execution while Shilpa retains development and sustained commercial supply responsibilities. The collaboration targets wider ...
This article reviews the use of Raman spectroscopy in a series of case studies to quickly identify the iron oxide compound(s), including magnetite and hematite, on the surface of representative ...
European Commission approval enables 2 mg/kg Q4W pegunigalsidase alfa for stable, ERT-treated adults, extending infusion intervals from Q2W to Q4W to lessen cumulative treatment burden. Evidence ...
M capital investment will retrofit a 45‑acre Athlone site for high-volume oral GLP‑1 tableting, with phased completion in 2027–2028 to de-risk CMC supply. Designating Athlone as a primary ex-US ...
Norgine invests £23 million in Wales site to modernize production and boost resilience for UK and European medicine supply chains.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results